Kiniksa Pharma: KPL-716 Phase 1a/1b Achieves Its Study Goals

(RTTNews) - Kiniksa Pharmaceuticals, Ltd. (KNSA) presented Phase 1a/1b clinical data for KPL-716, an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta. In the First-in-Human clinical trial, single intravenous and subcutaneous doses of KPL-716 were well-tolerated in both adult healthy volunteers and adult subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus. KPL-716 also demonstrated a reduction in pruritus. The company said the results support its plans for expanding clinical development into multiple chronic pruritic diseases, including prurigo nodularis.

"Data from the single-dose cohorts of the placebo-controlled Phase 1a/1b of KPL-716 achieved the goals established for the study. The results provided us with data on the safety and tolerability of KPL-716 as well as the anti-pruritic effect of the drug," said Sanj Patel, CEO and Chairman of the Board of Kiniksa.